In NSCLC, KEAP1 deficiency is commonly observed in LUAD, while activating alterations of NFE2L2 are more prevalent in squamous cell lung carcinoma (~20%), with both alterations being mutually exclusive (108). Here, KEAP1 is linked to non-small cell lung carcinoma.